## Clinical Context This patient presents with a classic triad of PE: dyspnea, pleuritic chest pain, and tachycardia. The elevated D-dimer, wedge-shaped infiltrate (Hampton's hump—pulmonary infarction), and haemodynamic stability are key features. ## Diagnostic Algorithm for Suspected PE ```mermaid flowchart TD A["Clinical suspicion of PE<br/>(dyspnea + chest pain + tachycardia)"]:::outcome --> B{"Haemodynamically<br/>stable?"}:::decision B -->|Yes| C{"High clinical<br/>probability?"}:::decision B -->|No| D["Massive PE<br/>Thrombolysis/Embolectomy"]:::urgent C -->|Yes| E["Start anticoagulation<br/>BEFORE imaging"]:::action C -->|No| F["D-dimer/CT angiography"]:::action E --> G["Obtain CTPA for<br/>confirmation"]:::action F --> H{"CTPA positive?"}:::decision G --> I{"PE confirmed?"}:::outcome H -->|Yes| J["Continue anticoagulation"]:::action H -->|No| K["Stop anticoagulation"]:::action ``` ## Key Management Principles **Key Point:** In haemodynamically stable patients with HIGH clinical probability of PE, anticoagulation should be initiated BEFORE imaging confirmation, provided there are no absolute contraindications. This reduces the risk of clot propagation and recurrent thromboembolism while awaiting diagnostic confirmation. **High-Yield:** The 2019 ESC Guidelines and most international protocols recommend: - **Stable PE + high clinical probability** → Start anticoagulation immediately, then confirm with CTPA - **Stable PE + low-intermediate probability** → D-dimer/CTPA first, then anticoagulate if positive In this case, the clinical picture is highly suggestive (dyspnea + pleuritic pain + tachycardia + elevated D-dimer + radiographic finding), justifying immediate anticoagulation. ## Anticoagulation in Stable PE | Agent | Dosing | Advantages | Use | |-------|--------|------------|-----| | **UFH** | 80 U/kg IV bolus, then 18 U/kg/hr infusion | Rapid onset, reversible, short half-life, renal clearance | First-line in haemodynamic instability; allows rapid reversal if bleeding | | **LMWH** | Enoxaparin 1 mg/kg SC BD or 1.5 mg/kg OD | Predictable pharmacokinetics, SC route | Stable outpatients; NOT first-line if thrombolysis anticipated | | **Fondaparinux** | Weight-based SC OD | Once-daily dosing | Alternative if HIT history | **Clinical Pearl:** UFH is preferred over LMWH in this setting because: 1. Rapid IV onset (minutes vs. hours) 2. Reversible with protamine if bleeding occurs 3. Allows rapid transition to thrombolysis if haemodynamic deterioration occurs 4. Shorter half-life permits safer monitoring ## Why CTPA Is Essential CTPA is the gold-standard imaging for PE diagnosis. It: - Confirms the diagnosis - Assesses clot burden and location - Evaluates for alternative diagnoses (pneumonia, aortic dissection, etc.) - Guides risk stratification (proximal vs. distal clots) ## Why NOT Thrombolysis Now **Warning:** Thrombolytic therapy is reserved for **massive (haemodynamically unstable) PE** or **submassive PE with RV dysfunction and haemodynamic compromise**. This patient is stable with normal BP and adequate oxygenation—thrombolysis carries significant bleeding risk without clear benefit. **Mnemonic for PE Risk Stratification:** **PERT** - **P**roximal clot (iliofemoral, pulmonary trunk) - **E**levated troponin or BNP - **R**ight ventricular dysfunction (echo/CT) - **T**achycardia + hypotension (haemodynamic instability) This patient has none of these high-risk features yet.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.